ArticleFrontiers in oncology2025
Anlotinib-induced renovascular hypertension and severe coronary artery stenosis: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anlotinib is a multi-target tyrosine kinase inhibitor that has been approved in China as a third-line treatment for advanced non-small cell lung cancer. It exerts anti-tumor effects by inhibiting tumor growth and tumor angiogenesis, and its toxicity also arises from this mechanism. Anlotinib can damage vascular endothelium, thereby inducing cardiovascular toxicity, which leads to hypertension, hyperlipidemia, accelerated atherosclerosis, and the initiation of atherosclerotic cardiovascular disease, ultimately resulting in life-threatening cardiovascular events. To the best of our knowledge, this study is the first case report documenting the development of hypertension, hyperlipidemia, hypothyroidism, subsequent discovery of bilateral renal artery stenosis, and acute myocardial infarction in a young patient receiving anlotinib treatment. This showed anlotinib may accelerate systemic large/medium-sized artery atherosclerosis in the context of complex tumor therapy, causing life-threatening cardiovascular events. Besides, it highlights the necessity of regular monitoring of relevant indicators during follow-up for patients undergoing anlotinib therapy, enabling early detection of warning signs and timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.